Caterina Ramogida

Assistant Professor, Joint with TRIUMF


  • B.Sc. (Hons), Simon Fraser University (2010)
  • Ph.D., University of British Columbia (2015)
  • Postdoctoral Research Fellow, TRIUMF (2015 – 2018)


Nuclear Medicinal Inorganic Chemistry

Nuclear medicine is a powerful technique with the ability to both image disease non-invasively and subsequently treat the diseased state by injecting a radioactive isotope fused to a designer molecule that can transport the radionuclide specifically to the diseased tissue.  Our research focuses on the development of novel pharmaceuticals which incorporate radioactive metal ions (aka radiometals) for both molecular imaging and targeted therapy of disease. We design, synthesize, characterize, and evaluate (in vitro and in vivo) metal-based radiopharmaceuticals, with an emphasis on understanding the coordination chemistry used to tether the radiometal ion to the biomolecular targeting vector (Figure 1). This interdisciplinary research bridges the fields of chemistry, biology, and radiology. We work closely with our collaborators at TRIUMF – Canada’s particle accelerator centre ( – to produce innovative and unconventional radiometals, and BC Cancer – to evaluate our radiopharmaceuticals in vivo.

To learn further about our research directions please visit the group website (and check out – a short documentary about Actinium-225, a promising alpha-emitting radionuclide that can be used for targeted therapy, and one of our research foci).

We are looking for enthusiastic undergraduate and graduate students to join our program!

Figure 1. Depiction of a metal-based radiopharmaceutical. The four primary components are (1) the chelating ligand, used to bind the radiometal ion in a tight and stable coordination complex, (2) the linker, incorporates a chemically reactive moiety which covalently binds to the targeting vector, (3) targeting vector, such as an antibody, peptide, or small molecule which generally has high affinity for surface receptors on diseased cells, and (4) a radiometal, which will emit particles that can be used to image disease (via gamma rays or positrons) or destroy diseased cells (via alpha, beta, or Auger electron emission).


1. Wang, X., Jaraquemada-Peláez, M. de G., Rodríguez-Rodríguez, C., Cao, Y., Buchwalder, C., Choudhary, N., Jermilova, U., Ramogida, C. F., Saatchi, K., Häfeli, U. O., Patrick, B. O., Orvig, C. (2018) H4octox: Versatile Bimodal Octadentate Acyclic Chelating Ligand for Medicinal Inorganic Chemistry.  J. Am. Chem. Soc. 140, 15487-15500.

2. Robertson, A.K.H., Ramogida, C.F, Schaffer, P., Radchenko, V. (2018) Development of 225Ac radiopharmaceuticals: TRIUMF perspectives and experiences. Current Radiopharmaceuticals. 11, 156-172. DOI:10.2174/1874471011666180416161908

3. Dias, G.M., Ramogida, C.F., Rousseau, J., Zacchia, N.A., Hoehr, C., Schaffer, P., Lin, K.-S., Bénard, F. (2018) 89Zr for antibody labelling and in vivo studies – a comparison between liquid and solid target production. Nuclear Medicine and Biology, 58, 1 – 7.  doi: 10.1016/j.nucmedbio.2017.11.005.

4. Thiele, N.A., Brown, V., Kelly, J.M., Amor-Coarasa, A., Jermilova, U., MacMillan, S.N., Nikolopoulou, A., Ponnala, S., Ramogida, C.F., Robertson, A.K.H., Rodríguez-Rodríguez, C., Schaffer, P., Williams, C.Jr., Babich, J.W., Radchenko, V., Wilson, J.J. (2017) An Eighteen-membered macrocyclic ligand for actinium-225 targeted alpha therapy. Angewandte Chemie., 57, 14712 – 14717. doi: 10.1002/anie.201709532 and 10.1002/ange.201709532.

5. Comba, P., Jermilova, U., Orvig, C., Patrick, B. O., Ramogida, C.F., Rück, K., Schneider, C., Starke, M. (2017) Octadentate picolinic acid-based bispidine ligand for radiometal ions. Chemistry A European Journal, 23, 15945-15956. doi: 10.1002/chem.201702284.

6. Spreckelmeyer, S., Ramogida, C.F., Rousseau, J., Arane, K., Bratanovic, I., Colpo, N., Jermilova, U., Dias, G.M., Dude, I., Jaraquemada-Peláez, M. de G., Bénard, F., Schaffer, P., Orvig, C. (2017) p-NO2-Bn-H4neunpa and H4neunpa-trastuzumab: Bifunctional chelator for radiopharmaceuticals and 111In immuno-SPECT imaging. Bioconjugate Chemistry, 28, 2145-2159.

7. Robertson, A.K.H., Ramogida, C.F., Rodriguez-Rodriguez, C., Blinder, S., Kunz, P., Sossi, V., Schaffer, P. (2017) Multi-isotope SPECT imaging of the 225Ac decay chain: feasibility studies. Physics in Medicine and Biology, 101, 158-162.

8. Weekes, D.M., Ramogida, C.F., Jaraquemada-Peláez, M.G., Patrick, B.O., Apte, C., Kostelnik, T.I., Cawthray, J.F., Murphy, L., Orvig, C. (2016) Dipicolinate complexes of gallium(III) and lanthanum(III). Inorganic Chemistry, 55, 12544-12558.

9. Ramogida, C.F., Schindler, D., Schneider, C., Tan, Y.L.K., Huh, S., Ferreira, C.L., Adam, M.J., Orvig, C. (2016) Synthesis and characterization of lipophilic cationic Ga(III) complexes based on the H2CHXdedpa and H2dedpa ligands and their 67/68Ga radiolabeling studies. RSC Advances, 6, 103763-103773.

10. Ramogida, C.F., Boros, E., Patrick, B.O., Zeisler, S. K., Kumlin, J., Adam, M.J., Schaffer, P., Orvig, C. (2016) Evaluation of H2CHXdedpa, H2dedpa- and H2CHXdedpa-N,N’-propyl-2-NI ligands for 64Cu(II) radiopharmaceuticals. Dalton Transactions, 45, 13082-13090.

11. Ramogida, C.F., Murphy, L., Cawthray, J.F., Ross, J.D., Adam, M.J., Orvig, C. (2016) Novel “bi-model” H2dedpa derivatives for radio- and fluorescence imaging. Journal of Inorganic Biochemistry, 162, 253-262. Invited for Prof. G. R. Hanson Memorial issue.

12. Ramogida, C.F., Pan, J., Ferreira, C. L., Patrick, B.O., Rebullar, K., Yapp, D.T.T., Lin, K-.S., Adam, M.J., Orvig, C. (2015) Nitroimidazole-containing H2dedpa and H2CHXdedpa derivatives as potential PET imaging agents of hypoxia with 68Ga. Inorganic Chemistry, 54, 4953-4965.

13. Ramogida, C.F., Cawthray, J.F., Boros, E., Ferreira, C.L., Patrick, B.O., Adam, M.J., Orvig, C. (2015) H2CHXdedpa and H4CHXoctapa – Chiral acyclic chelating ligands for 67/68Ga and 111In radiopharmaceuticals. Inorganic Chemistry, 54, 2017-2031.

14. Ramogida, C.F., Orvig, C. (2013) Tumour targeting with radiometals for diagnosis and therapy. Chemical Communications, 49, 4720-4739.

15. Price, E.W., Zeglis, B.M., Cawthray, J.F., Ramogida, C.F., Ramos, N., Lewis, J.S., Adam, M.J., Orvig, C. (2013) H4octapa-Trastuzumab: Versatile acyclic chelate system for 111In and 177Lu imaging and therapy. Journal of the American Chemical Society, 135, 12707-12721.

16. Dunn, T.J., Chiang, L., Ramogida, C.F., Hazin, K., Webb, M.I, Katz, M.J., Storr, T. (2013) Class III delocalization and exciton coupling in a bimetallic bis-ligand radical complex. Chemistry – A European Journal, 19, 9606-9618.

17. Dunn, T.J., Chiang, L., Ramogida, C.F., Webb, M.I., Savard, D., Sakaguchi, M., Ogura, T., Shimazaki, Y., Storr, T. (2012) Non-innocent ligand behaviour of a bimetallic Cu complex employing a bridging catecholate. Dalton Transactions, 41, 7905-7914.

18. Dunn, T.J., Ramogida, C.F., Simmonds, C., Paterson, A., Wong, E.W.Y., Chiang, L., Shimazaki, Y., Storr, T. (2011) Non-innocent ligand behaviour of bimetallic Ni Schiff-base complex containing a bridging catecholate. Inorganic Chemistry, 50, 6746-6755.

19. Shimazaki, Y., Arai, N., Dunn, T.J., Yajima, T., Tani, T., Ramogida, C.F., Storr, T. (2011) Influence of the chelate effect on the electronic structure of one-electron oxidized group 10 metal(II)-disalicylidene diamine complexes. Dalton Transactions, 40, 2469-2479.

20. Van Donkersgoed, J., Sit, D., Gibbons, N., Ramogida, C., Hendrick, S. (2010) Drug residues recovered in feed after various feedlot mixer truck cleanout procedures. Journal of Food Protection, 6, 75-80.


Future courses may be subject to change.